Quantification pitfalls in comparative studies of antianginal therapies.
D000787:Angina Pectoris / Q000188:drug therapy*; D004341:Drug Evaluation; D004983:Ethanolamines / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008013:Lidoflazine / Q000627:therapeutic use*; D005996:Nitroglycerin / Q000627:therapeutic use*; D010096:Oxprenolol / Q000627:therapeutic use*; D010647:Phenyl Ethers / Q000627:therapeutic use; D005082:Physical Exertion; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos; D013223:Statistics as Topic; D014665:Vasodilator Agents / Q000627:therapeutic use*
D004983:Ethanolamines; D010647:Phenyl Ethers; D010879:Piperazines; D010919:Placebos; D014665:Vasodilator Agents; D010096:Oxprenolol; D005996:Nitroglycerin; D008013:Lidoflazine